J2A-MC-GZPL: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION); J2A-MC-GZL1: Participants with Hypertension and Obesity or Overweight; J2A-MC-GZL2: Participants with Hypertension and Obesity or Overweight

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519000-27-00

Acronym

J2A-MC-GZPL

Enrollment

422

Registered

2025-07-02

Start date

2025-07-17

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

(GZPL) Number of Participants Allocated to Each Study [Time Frame: Week -8 to Week 0] (GZL1; GZL2) Change from Baseline in office SBP [Time Frame: Baseline to Week 36]

Interventions

DRUGORFORGLIPRON

DRUGPlacebo to match LY

DRUGOrforglipron

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
(GZPL) Number of Participants Allocated to Each Study [Time Frame: Week -8 to Week 0] (GZL1; GZL2) Change from Baseline in office SBP [Time Frame: Baseline to Week 36]	—

Countries

Czechia, Germany, Greece, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026